Last Updated : March 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Evra | Norgelestromin/ethinyl estradiol | Contraceptive, patch | Do not list | Complete | ||
Iressa | Gefitinib | Cancer, Lung , non-small cell | Do not list | Complete | ||
Axert | Almotriptan | Migraine | List in a similar manner to other drugs in class | Complete | ||
Replagal | Agalsidase alfa | Fabry Disease | Do not list | Complete | ||
Viread | Tenofovir disoproxil fumarate | HIV infection | Do not list | Complete | ||
Fabrazyme | Agalsidase beta | Fabry Disease | Do not list | Complete | ||
Neulasta | Pegfilgrastim | Neutropenia | List with clinical criteria and/or conditions | Complete | ||
Adderall XR | Mixed amphetamine salts | Attention deficit hyperactivity disorder | Do not list | Complete | ||
Zavesca | Miglustat | Gaucher disease | Do not list | Complete | ||
Pegasys RBV | Peginterferon alfa-2a and Ribavirin | Hepatitis C, chronic | List in a similar manner to other drugs in class | Complete |